Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Graves’ Disease Treatment Revolution: What’s Next in Line?
The market for Graves’ disease treatments is anticipated to increase, driven by increasing disease awareness, better diagnostic tools, and the expansion of targeted biologic therapies. As per DelveInsight analysis, the Graves’ disease market size in the 7MM was around USD 4.4 billion in 2023 and is expected to increase with a significant CAGR during the forecast period.
Everything You Need to Know About Acute Kidney Injury
Articles
Jan 17, 2025
Johnson & Johnson MedTech Secures CE Mark for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter; Medtronic Secures CE Mark for BrainSense™ Adaptive Deep Brain Stimulation; Inquis Medical Finalizes Enrollment for U.S. Pivotal Study on Aventus Thrombectomy System for Pulmonary Embolism; First Patient Enrolled in Argon Medical’s CLEAN-PE Study for Novel Pulmonary Embolism Therapy; Sutter Health and GE HealthCare Partner to Revolutionize Patient Care with AI-Driven Imaging Solution; Saluda Medical Closes $100M Financing to Expand Neuromodulation Portfolio
Notizia - Recent Pharma, Healthcare and Biotech Happenings
Jan 16, 2025
What Does the Future Hold for Acute Kidney Injury? A Deep Dive into the Evolving Pipeline
Articles
Jan 16, 2025
Breakthrough Therapies Shaping the Future of Acute Kidney Injury Treatment
Articles
Jan 16, 2025
Exploring the Future of Acute Kidney Injury: Market Trends and Growth Opportunities
Articles
Jan 16, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper
The therapy for aHUS is primarily supportive, focusing on managing acute kidney injury and systemic complications, with renal replacement therapy required for patients with uremia, fluid overload, or electrolyte abnormalities. Specific treatments include plasma exchange and complement inhibitors like eculizumab and ravulizumab, the only two approved drugs for aHUS treatment. In 2023, the total market size for aHUS in the United States was ~USD 900 million and is projected to surpass USD 1.5 billion by 2034, growing at a CAGR of 4.5% from 2020 to 2034. Among emerging therapies, PIASKY (crovalimab) and FABHALTA (iptacopan) are expected to significantly impact the market.
A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.
A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.
A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.
A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.
A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.